Cantor Fitzgerald Forecasts GH Research FY2024 Earnings

GH Research PLC (NASDAQ:GHRS) – Cantor Fitzgerald issued their FY2024 earnings per share estimates for GH Research in a research note issued on Thursday, February 13th. Cantor Fitzgerald analyst C. Duncan expects that the company will post earnings per share of ($0.79) for the year. Cantor Fitzgerald has a “Overweight” rating and a $14.00 price target on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share. Cantor Fitzgerald also issued estimates for GH Research’s FY2025 earnings at ($0.80) EPS.

GHRS has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of GH Research in a report on Monday, January 27th. Canaccord Genuity Group decreased their price objective on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th.

GH Research Stock Performance

GHRS opened at $14.31 on Monday. The stock has a fifty day simple moving average of $9.73 and a two-hundred day simple moving average of $9.09. The company has a market cap of $744.52 million, a price-to-earnings ratio of -18.11 and a beta of 0.93. GH Research has a 12-month low of $6.00 and a 12-month high of $20.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new position in shares of GH Research during the 4th quarter valued at about $44,000. Two Sigma Investments LP purchased a new position in shares of GH Research during the 4th quarter valued at about $117,000. Millennium Management LLC bought a new stake in GH Research during the 4th quarter valued at approximately $145,000. AdvisorShares Investments LLC raised its stake in GH Research by 15.4% during the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock valued at $252,000 after purchasing an additional 4,806 shares during the period. Finally, Northern Trust Corp raised its stake in GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after purchasing an additional 8,641 shares during the period. 56.90% of the stock is owned by hedge funds and other institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).